Erratum: Update on the EFFECTS study of fluoxetine for stroke recovery: A randomised controlled trial in Sweden (Trials (2020) 21:233 DOI: 10.1186/s13063-020-4124-7);Update on the EFFECTS study of fluoxetine for stroke recovery: A randomised controlled trial in Sweden

Trials

Volumn 21, Issue 1, 2020, Pages

  Lundström, Erik ^a   Isaksson, Eva ^b   Näsman, Per ^c   Wester, Per ^d,e   Mårtensson, Björn ^b   Norrving, Bo ^f   Wallén, Håkan ^d   Borg, Jörgen ^d   Dennis, Martin ^g   Mead, Gillian ^g   Hankey, Graeme J ^h   Hackett, Maree L ^i,j   Sunnerhagen, Katharina S ^k,l,m,n   Laska, Ann Charlotte ^o   Gudmundsson, Bjarni ^o   Cederin, Björn ^o   Esbjörnsson, Magnus ^o   Wiberg, Bernice ^o   Lantz, Maria ^o   Teichert, Jörg ^o   Bergmann, Magnus ^o   Welin, Lennart ^o   Löfmark, Ulrika ^o   Bysell, Sven Erik ^o   Hu, Xiaolei ^o   Andersson, Axel ^o   Gunnarsson, Moa ^o   Sandgren, Pernilla ^o   Ask, Eva ^o   Sommer, Peter Thomasson ^o   Danielsson, Bo ^o   Hopia, Liisa ^o   Arvidsson, Andreas ^o   Björck, Fredrik ^o   Brederlau, Anke ^o   Ulfarsson, Trandur ^o   Taklif, Mehran ^o   Gibson, Magnus ^o   Eklund, Brita ^o   Hedström, Björn ^o   Richardsson, Ellinore ^o   Merrick, Daniel ^o   Broman, Per ^o   Mademyr Larsson, Max ^o   Ranhem, Andreas ^o   Ronnheden, Camilla ^o   Johansson, Martin ^o   Onkenhout, Anette ^o   more..

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^k UNIVERSITY OF GOTHENBURG   (Sweden)

^l RIGA STRADINS UNIVERSITY   (Latvia)

^m Sunnaas Rehabilitation Hospital   (Norway)

ⁿ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^o NONE

more..

Author keywords

Fluoxetine; Multicentre study; Recovery of function; Selective serotonin reuptake inhibitor; SSRI; Stroke; Stroke recovery

Indexed keywords

FLUOXETINE; METOPROLOL; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CONVALESCENCE; DISEASE REGISTRY; DRUG CAPSULE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE; HEALTH CENTER; HEART FAILURE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE PATIENT; SWEDEN; TREATMENT DURATION; DRUG ADMINISTRATION; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; STROKE; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 85080877178     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-020-04327-w     Document Type: Erratum

References (20)

1. Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D, et al. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:439-58.
2. Riksstroke. Riksstroke results 2018. Available from: http://www.riksstroke.org/wp-content/uploads/2019/09/Riksstroke_A%CC%8Arsrapport-2018_slutversionWEB.pdf. Cited 13 Sept 2019.
3. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545-602.
4. Chollet F, Tardy J, Albucher J-F, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123-30.
5. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Inter-observer agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-7.
6. Mead GE, Hsieh C-F, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012; John Wiley & Sons, Ltd. Available from: http://onlinelibrary.wiley.com.proxy.kib.ki.se/doi/10.1002/14651858.CD009286.pub2/abstract. Cited 27 Sept 2015.
7. Mead G, Hackett ML, Lundström E, Murray V, Hankey GJ, Dennis M. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials. 2015;16:369.
8. Dennis M, Mead G, Forbes J, Graham C, Hackett M, Hankey GJ, et al. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019;393:265-74.
9. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200.
10. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
11. Graham C, Lewis S, Forbes J, Mead G, Hackett ML, Hankey GJ, et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials. 2017;18:627.
12. Lundström, E. Protocol and Ethics | EFFECTS. Available from: http://www.effects.se/english/protocol-and-ethics. Cited 9 Sept 2019.
13. Franklin M, Thorn J. Self-reported and routinely collected electronic healthcare resource-use data for trial-based economic evaluations: the current state of play in England and considerations for the future. BMC Med Res Methodol. 2019;19:8.
14. Swedish Institute. Healthcare in Sweden. 2015. Available from: https://sweden.se/society/health-care-in-sweden/. Cited 22 July 2019.
15. Asplund K, Sukhova M, Wester P, Stegmayr B, Riksstroke Collaboration. Diagnostic procedures, treatments, and outcomes in stroke patients admitted to different types of hospitals. Stroke. 2015;46:806-12.
16. Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, et al. Update on the third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials. 2011;12:252.
17. Svensk Läkemedelsförsäkring AB. Läkemedelsförsäkringen - a unique type of insurance. Available from: https://lff.se/a-unique-type-of-insurance/for-patients/. Cited 19 Aug 2019.
18. IST-3 Collaborative Group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet. 2012;379:2352-63.
19. ICMJE | Recommendations | Defining the Role of Authors and Contributors. Available from: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html. Cited 23 July 2019.
20. Branting, Kristina. KI ELN - the electronic notebook. Available from: https://staff.ki.se/ki-eln-the-electronic-notebook. Cited 19 Aug 2019.